
Allied Minds appoints Amgen CEO to board
pharmafile | June 8, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â allied minds, kevin sharerÂ
US science and tech development and commercialisation firm Allied Minds has appointed Kevin Sharer to its board of directors.
Sharer joins the firm from Amgen which he led for two decades, starting as its president and chief operating officer in 1992, and then eventually taking over as chief executive and chairman.
Following a career in the Navy Sharer honed his business skills by working at McKinsey & Co as a consultant, at General Electric in corporate development, and at MCI Telecommunications as an executive vice president in marketing.
Having recently served on the boards of Chevron and Northrop Grumman Corp, Sharer is currently a member of the faculty at Harvard Business School.
Chris Silva who is the chief executive of Allied Minds, says: “We are delighted with the appointment of Kevin Sharer to our board of directors. He is a seasoned executive with a strong and highly relevant track record of successfully developing and commercialising new and disruptive science and technologies.






